We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+16.16%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$59.8M
Cap. Flow
+$91.1M
Cap. Flow %
8.85%
Top 10 Hldgs %
91.97%
Holding
24
New
3
Increased
2
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SGP
SpyGlass Pharma
SGP
+$56.8M
2
STRO icon
Sutro Biopharma
STRO
+$15.5M
3
ALMS
Alumis Inc
ALMS
+$14.7M
4
AGMB
AgomAb Therapeutics NV
AGMB
+$8.5M
5
CHRS icon
Coherus Oncology
CHRS
+$6.09M

Top Sells

Rank Stock Value
1
PVLA
Palvella Therapeutics
PVLA
+$6.92M
2
ABVX
Abivax
ABVX
+$2.23M
3
CTNM
Contineum Therapeutics
CTNM
+$826K
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$477K
5
NUVB.WS
Nuvation Bio Inc Warrants
NUVB.WS
+$41K

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return

Samsara BioCapital's Q1 2026 Portfolio in Review

As of Q1 2026, Samsara BioCapital held 24 positions worth $1.03B, up 6.2% from $969M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Samsara BioCapital deployed $91.1M of net new capital in Q1 2026, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was SpyGlass Pharma: 2,109,953 shares worth $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Palvella Therapeutics, an estimated $6.92M trimmed.

  • Samsara BioCapital's largest Q1 2026 buy was SpyGlass Pharma: 2,109,953 shares worth $54.7M.
  • Samsara BioCapital added most to Sutro Biopharma in Q1 2026, an estimated $15.5M increase.
  • Samsara BioCapital's biggest Q1 2026 reduction was Palvella Therapeutics, cutting an estimated $6.92M.
  • Samsara BioCapital fully exited Contineum Therapeutics in Q1 2026, selling an estimated $826K.
  • Samsara BioCapital's ten largest holdings make up 92% of its $1.03B portfolio in Q1 2026.
  • Samsara BioCapital opened 3 new positions and closed 2 in Q1 2026.
  • Samsara BioCapital's portfolio value rose 6.2% quarter-over-quarter to $1.03B.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.